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Introduction: Erlotinib has prolonged survival in unselected pa-
tients with advanced non-small cell lung cancer, whereas sunitinib
has yielded promising rates of disease control in previously treated
patients. We conducted a dose escalation study of this combination
to determine the maximum tolerated dose of sunitinib in combina-
tion with a fixed dose of erlotinib and to evaluate the toxicities of
this combination.
Methods: Patients with advanced nonsquamous non-small cell lung
cancer were treated at two dose levels: sunitinib at either 25 mg or
37.5 mg, with erlotinib 150 mg. Both drugs were given once daily,
continuously.
Results: Eleven patients enrolled from November 2007 to October
2009. No dose-limiting toxicities occurred. Grade 3/4 adverse events
at least possibly related to treatment were seen in seven patients
(64%). Six patients (54%) required dose modifications, and three
(27%) discontinued study treatment due to toxicity. Rates of grade
3 diarrhea and mucositis exceeded those seen with single-agent
erlotinib or sunitinib. One patient (9%) attained a partial response
lasting 16.3 months.
Conclusions: Although no dose-limiting toxicities occurred, it is
difficult to recommend erlotinib 150 mg and sunitinib 37.5 mg daily
as the phase II dose for this combination due to the high rate of
adverse events. Because of the overlapping toxicity profile of each
agent, this combination was poorly tolerated in our population.
Key Words: Phase I clinical trial, Non-small cell lung cancer,
Epidermal growth factor receptor, Vascular endothelial growth fac-
tor receptors, Receptor protein-tyrosine kinases.
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Treatment with erlotinib, an epidermal growth factor re-ceptor (EGFR) tyrosine kinase inhibitor (TKI), has pro-
longed survival and improved symptom control in unselected
patients with advanced non-small cell lung cancer (NSCLC).1
Sunitinib, an oral multitargeted TKI of vascular endothelial
growth factor (VEGF) receptor (VEGFR) -1, -2, and -3, and
platelet-derived growth factor receptor- and -, has demon-
strated modest efficacy as a single agent in advanced NSCLC.2,3
Both preclinical and clinical evidence support simulta-
neous blockade of EGFR and VEGFR pathways. Laboratory
evidence has shown that both tumor- and host-derived VEGF
expression were elevated in models of EGFR TKI primary
and acquired resistance and that exposure of these resistant
models to the dual VEGFR and EGFR TKI vandetanib
significantly inhibited tumor growth.4,5 Clinically, progres-
sion-free survival was lengthened when bevacizumab was
added to erlotinib in the maintenance6 and second-line set-
tings of advanced NSCLC,7 compared with single-pathway
suppression. Similarly, vandetanib prolonged progression-
free survival compared with EGFR blockade alone using
gefitinib.8 Therefore, we sought to assess the safety of the
combination of sunitinib and erlotinib in patients with ad-
vanced nonsquamous NSCLC.
PATIENTS AND METHODS
Patients of good performance status with advanced
nonsquamous NSCLC were eligible, provided they had not
previously been treated with prior EGFR or VEGFR inhibi-
tors. Patients with squamous cell histology were excluded
due to concerns regarding the potential risk of hemorrhage in
this population using sunitinib.9 Each patient gave written
informed consent, according to institutional and federal
guidelines. The protocol was approved by the University of
Wisconsin-Madison Institutional Review Board.
This dose escalation trial was designed to determine the
safety, tolerability, and maximum tolerated dose (MTD) of
sunitinib combined with erlotinib in patients with advanced
nonsquamous NSCLC of any line of therapy. Patients re-
ceived erlotinib, 150 mg, and sunitinib at either 25 mg (dose
level 1) or 37.5 mg (dose level 2). Both drugs were given
once daily, continuously, during a 21-day cycle.
Dose escalation followed a traditional 3  3 phase I
trial design, with the MTD defined as the highest dose level
at which 0 or 1 of 6 evaluable patients experienced dose-limiting
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toxicities (DLTs) and was expanded to six patients to more fully
characterize safety of this combination. DLTs were assessed
through cycle 1 of treatment, were judged to be probably or
definitely related to either sunitinib or erlotinib, and included
febrile neutropenia, neutropenic infection, grade 3 thrombo-
cytopenia with bleeding, grade 4 thrombocytopenia lasting 7
days, and grade 3 nonhematologic toxicities lasting 7 days,
other than nausea, vomiting, or diarrhea unresponsive to maxi-
mal supportive therapy. Toxicities were evaluated per National
Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) version 3.
The primary objective of the study was determination
of the MTD. Secondary objectives included measurement of
antitumor response. Demographics, toxicities, and tumor re-
sponses were summarized with descriptive statistics such as
frequencies, percentages, median, and range of minimum and
maximum. The 95% confidence interval (CI) for the response
rate at the MTD was constructed using Wilson’s score
method, and the Kaplan-Meier (product limit) method was
used to estimate the survival function for overall survival. All
patients were evaluable for safety and toxicity. The efficacy
analysis was based on the intent-to-treat principle.
RESULTS
Eleven patients enrolled from November 2007 to October
2009. Median follow-up duration of this study was 9.3 months.
Pretreatment characteristics are summarized in Table 1. The
dose escalation schema is given in Table 2. Four patients were
enrolled on dose level 1 (sunitinib 25 mg daily), whereas seven
were enrolled on dose level 2 (sunitinib 37.5 mg daily). One
patient at each of the two dose levels were replaced due to not
completing cycle 1 of therapy for reasons other than toxicity:
one patient in dose level 1 was removed from the study due to
investigator discretion when a subsequent review of his screening
imaging revealed multiple cavitary pulmonary lesions, and one
patient on dose level 2 withdrew consent. Pill diaries revealed that
treatment compliance with this combination measured 90.6%.
No DLTs were observed. Per protocol definition, the MTD
was dose level 2 (sunitinib 37.5 mg with erlotinib 150 mg).
There were no deaths on study. Four serious adverse
events occurred. Two patients died within 30 days of coming off
treatment, both due to disease progression. A 70-year-old male
patient enrolled on dose level 1 was hospitalized during cycle 2
for grade 3 abdominal pain and ileus possibly related to treat-
ment. In addition, a 75-year-old male patient enrolled on dose
level 2 was admitted during cycle 1 of treatment with grade 2
rapid atrial fibrillation and grade 3 left ventricular dysfunction
possibly related to treatment. The atrial fibrillation occurred after
a protocol-mandated change in the patient’s rate control agent.
Three patients (27%) discontinued study treatment due to tox-
icities, six patients due to progressive disease, one due to
withdrawal of consent, and one due to investigator discretion.
Six patients (54%) had their treatment doses held or
reduced due to adverse events, four of whom never resumed
treatment. Grade 3 and grade 4 adverse events at least possibly
related to treatment occurred in seven patients (64%), as seen in
Table 3. Rates of grade 3 diarrhea and mucositis exceeded those
seen with single-agent erlotinib or sunitinib.
The most common toxicities encountered with this regi-
men were dermatologic (eight episodes of acneiform rash and
three of hand-foot reaction), diarrhea (including two grade 3
TABLE 2. Dose Escalation Schema
Dose Level
Sunitinib
(mg/d)
Erlotinib
(mg/d) N
No. of
Cycles
2 25 50
1 25 100
1a 25 150 4 9
2 37.5 150 7 36
a Dose escalation started with dose level 1.
TABLE 3. Grade 3 and Grade 4 Toxicities, At Least Possibly
Related to Treatment
Toxicity
No. of Patients
(N  11)
Dose Level
Sunitinib
25 mg/d
Sunitinib
37.5 mg/d
Pulmonary embolisma 1 0 1
Diarrhea 2 1 1
Hand-foot skin reaction 1 0 1
Mucositis 1 0 1
Hypertension 1 0 1
Left ventricular dysfunction 1 0 1
Leukopenia 1 1 0
Abdominal pain with ileus 1 1 0
a Grade 4 toxicity; all other toxicities were grade 3.
TABLE 1. Patient Demographics
No. of patients 11
Median age (range) 64 yr (48–78 yr)
Sex
Male 5
Female 6
Performance status
0 5
1 6
Histology
Adenocarcinoma 9
NSCLC (not otherwise specified) 2
Prior cytotoxic regimens
0 1
1 10
Median time since prior treatment (range) 4.3 mo (1–21 mo)
Best response to prior cytotoxic treatment
Complete response 1
Partial response 3
Stable disease 4
Progressive disease 2
Unknown 1
Patients evaluable for
Safety 11
Efficacy 11
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occurrences), fatigue, mucositis, and lymphopenia. One asymp-
tomatic patient experienced the radiographic incidental finding
of a grade 4 pulmonary embolism. Six patients experienced
grade 3 toxicity as their worst grade of toxicity, and four patients
experienced grade 2 toxicity as their worst grade.
One patient (9%) attained a partial response lasting
16.3 months, whereas two patients (18%) experienced stable
disease for four cycles, and one patient (9%) had stable
disease for two cycles. The disease control rate was 36%
(95% CI: 15–65%). The median overall survival and 1-year
estimated overall survival were 9.3 months (95% CI: 1.7–
23.9 months) and 46% (95% CI: 17–71%), respectively.
DISCUSSION
Toxicity was increased using this regimen in our lim-
ited patient sample. Sixty-four percent of patients experi-
enced grade 3 and grade 4 adverse events, resulting in 54% of
patients reducing and/or holding their doses, a frequency
exceeding the rate of dose modifications with either agent
alone.1–3 Our rates of grade 3 mucositis and diarrhea were
increased compared with rates seen with single-agent erlo-
tinib or sunitinib.1–3 No new, unexpected toxicities were
encountered, but rather, they mirrored the overlapping off-
target toxicity profiles of fatigue, dermatologic, and gastro-
intestinal adverse events seen with each agent alone. It is
difficult to conclude if toxicities in our population were dose
dependent, as seven patients enrolled in dose level 2, whereas
only four enrolled in dose level 1.
Our increased rate of off-target adverse events with com-
bination targeted treatment was not unique. Ryan et al.10 de-
tected higher rates of dose reductions and interruptions, com-
pared with each single agent, when using this same combination
in patients with advanced renal cell carcinoma. Similarly, pub-
lished studies using the combination of erlotinib and sorafenib
found higher frequencies of dose modifications compared with
each agent alone, with toxicities consisting primarily of in-
creased rates of dermatologic and gastrointestinal adverse
events.11–13 Thus, it seems that combining targeted agents with
overlapping off-target toxicity profiles, as was the case with our
combination, leads to enhanced rates of dose delays and reduc-
tions due to adverse events.
A significant limitation of our study is that we did not
perform pharmacokinetic analyses. The need for pharmacoki-
netic evaluation is especially critical when using oral agents, in
which absorption may be variable,14 and when combining agents
characterized by similar toxicity profiles that may then result in
increased rates of dose reductions. Additional limitations of our
study include the small sample size and the absence of predictive
biomarkers that could have enriched our population for response
from dual pathway inhibition.
Efficacy outcomes were secondary endpoints in this
small dose escalation study, so although promising, it is not
appropriate to draw conclusions from them. A goal of dual
EGFR and VEGFR pathway inhibition is that simultaneous
blockade may reverse both primary and acquired resistance to
EGFR TKIs.4,5 We cannot conclude from our limited patient
population that this rationale was verified. The clinical rele-
vance of dual pathway inhibition will remain uncertain in
NSCLC, in either EGFR mutation-positive or -negative pa-
tients, until both efficacy and toxicity outcomes from a phase
III study of this combination are analyzed completely.15
In conclusion, our rates of dose modifications due to
treatment-related toxicities suggest that this combination was
poorly tolerated at either dose of sunitinib. The impact of our
frequent dose modifications on potential target modulation is
unknown as pharmacokinetic analyses were not performed
and as our study was not designed to estimate efficacy. Future
evaluation of this combination in advanced NSCLC should be
performed in a biomarker-determined population.
ACKNOWLEDGMENTS
Supported by Pfizer, Inc., New York City, NY, and
Genentech, Inc., South San Francisco, CA.
REFERENCES
1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously
treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
2. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous
daily sunitinib dosing in patients with previously treated advanced
non-small cell lung cancer. Br J Cancer 2009;101:1543–1548.
3. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of
sunitinib in previously treated, advanced non-small-cell lung cancer.
J Clin Oncol 2008;26:650–656.
4. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endo-
thelial growth factor receptor and epidermal growth factor receptor
(EGFR) blockade inhibits tumor growth in xenograft models of EGFR
inhibitor resistance. Clin Cancer Res 2009;15:3484–3494.
5. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474,
a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in
human cancer cells with acquired resistance to antiepidermal growth
factor receptor therapy. Clin Cancer Res 2004;10:784–793.
6. Kabbinavar F, Miller V, Johnson BE, et al. Overall survival (OS) in
ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or
without erlotinib (E) after completion of chemotherapy (chemo) with B
first-line treatment of locally advanced, recurrent, or metastatic non-
small cell lung cancer (NSCLC). J Clin Oncol 2010;28:544s.
7. Herbst RS, Stern H, Amler L, et al. Biomarker evaluation in the phase
III, placebo (P)-controlled, randomized beta trial of bevacizumab (B)
and erlotinib (E) for patients (Pts) with advanced non-small cell lung
cancer (NSCLC) after failure of standards 1st-line chemotherapy: cor-
relation with treatment outcomes. J Thorac Oncol 2009;9:S323.
8. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in
patients with advanced non-small-cell lung cancer: results from a two-part,
double-blind, randomized phase ii study. J Clin Oncol 2009;27:2523–2529.
9. Socinski MA. The current status and evolving role of sunitinib in
non-small cell lung cancer. J Thorac Oncol 2008;3:S119–S123.
10. Ryan CW, Curti BD, Quinn DI, et al. A phase II study of sunitinib (S)
plus erlotinib (E) in advanced renal carcinoma (RCC). J Clin Oncol
2010;28:348s.
11. Lind JS, Dingemans AM, Groen HJ, et al. A multicenter phase II study
of erlotinib and sorafenib in chemotherapy-naive patients with advanced
non-small cell lung cancer. Clin Cancer Res 2010;16:3078–3087.
12. Quintela-Fandino M, Le Tourneau C, Duran I, et al. Phase I combination
of sorafenib and erlotinib therapy in solid tumors: safety, pharmacoki-
netic, and pharmacodynamic evaluation from an expansion cohort. Mol
Cancer Ther 2010;9:751–760.
13. Duran I, Hotte SJ, Hirte H, et al. Phase I targeted combination trial of
sorafenib and erlotinib in patients with advanced solid tumors. Clin
Cancer Res 2007;13:4849–4857.
14. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents
across therapeutic areas: differences between oncology and non-oncol-
ogy products. Clin Cancer Res 2010;16:4446–4451.
15. Scagliotti GV, Krzakowsi M, Szczesna A, et al. Sunitinib (SU) in
combination with erlotinib (E) for the treatment of advanced/metastatic
non-small cell lung cancer (NSCLC): a phase III study. Ann Oncol
2010;21:viii3.
Journal of Thoracic Oncology • Volume 6, Number 5, May 2011 Phase I Study of Sunitinib and Erlotinib
Copyright © 2011 by the International Association for the Study of Lung Cancer 953
